Organization | Centre Paul Strauss

Centre Paul Strauss Report issue

Academic/Hospital Phase 2

Founded: Strasbourg France (1923)

Organization Overview

First Clinical Trial

1997

NCT00003654

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Alternative names

Centre Paul Strauss | Centre Paul Strauss 67065 Strasbourg | Centre Paul Strauss-Strasbourg | Centre Paul Strauss, Strasbourg | Centre Paul Strauss-STRASBOURG

Active Ingredients

Drugs in Phase 2 Trials (12)

adecatumumab (1 trial)

afatinib (gilotrif) (1 trial)

bevacizumab (avastin) (1 trial)

carboplatin (paraplatin) (1 trial)

cetuximab (erbitux) (3 trials)

cisplatin (platinol) (1 trial)

epirubicin (ellence) (1 trial)

etoposide (vepesid) (1 trial)

fluorouracil (efudex) (2 trials)

irinotecan (Camptosar) (1 trial)

leucovorin (2 trials)

oxaliplatin (eloxatin) (2 trials)

Drugs in Other Trials (2)

patent blue v dye (2 trials)

technetium tc-99m sulfur colloid kit (Tesuloid) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Disease Progression (Phase 2)

Head and Neck Neoplasms (Phase 2)

Liver Neoplasms (Phase 2)

Medulloblastoma (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 9
# of Trial APIs: 14